13 studies found for:    Kansas HCC sorafenib
Show Display Options
Rank Status Study
1 Recruiting Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Conditions: Adult Primary Hepatocellular Carcinoma;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer
Interventions: Drug: sorafenib tosylate;   Other: placebo;   Drug: doxorubicin hydrochloride;   Drug: doxorubicin-eluting beads;   Drug: cisplatin;   Drug: mitomycin C;   Other: pharmacological study
2 Recruiting Study of G-202 as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma
Condition: Advanced Adult Hepatocellular Carcinoma
Intervention: Drug: G-202
3 Active, not recruiting Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Nexavar (Sorafenib, BAY43-9006);   Drug: Placebo
4 Recruiting Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Recurrent Adult Primary Liver Cancer;   Stage C Adult Primary Liver Cancer (BCLC);   Stage D Adult Primary Liver Cancer (BCLC)
Interventions: Drug: doxorubicin hydrochloride;   Drug: sorafenib tosylate;   Other: laboratory biomarker analysis;   Other: pharmacological study
5 Recruiting A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma (HCC)
Interventions: Drug: E7080;   Drug: Nexavar
6 Unknown  Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Condition: Liver Cancer
Interventions: Biological: bevacizumab;   Drug: sorafenib tosylate
7 Completed Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib
Condition: Carcinoma, Hepatocellular
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
8 Active, not recruiting
Has Results
Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006);   Drug: Sorafenib (Nexavar, BAY43-9006) + Erlotinib, Tarceva
9 Recruiting Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib
Condition: Hepatocellular Carcinoma
Interventions: Drug: Cabozantinib (XL184);   Drug: Placebo
10 Completed Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
Conditions: Childhood Hepatocellular Carcinoma;   Papillary Thyroid Cancer;   Previously Treated Childhood Rhabdomyosarcoma;   Recurrent Childhood Liver Cancer;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Thyroid Cancer;   Recurrent Wilms Tumor and Other Childhood Kidney Tumors
Interventions: Drug: sorafenib tosylate;   Other: pharmacological study;   Other: laboratory biomarker analysis
11 Suspended Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma
Condition: Advanced Hepatocellular Carcinoma
Interventions: Drug: INC280;   Drug: Placebo
12 Completed Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.
Condition: Carcinoma
Intervention: Drug: Everolimus
13 Active, not recruiting Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: Dovitinib;   Drug: Sorafenib

Indicates status has not been verified in more than two years